Beta cryptoxanthin compositions and methods are described for the management of cardiometabolic syndrome and associated risk factors in a subject in need thereof. Methods herein are directed to identifying such subject at risk of developing cardiometabolic syndrome and administering beta cryptoxanthin composition to assess the condition of an organ. Compositions and methods herein can effectively reduce risk factors of cardiometabolic syndrome such as hyperlipidemia insulin resistance obesity diabetes atherosclerosis and/or related cardiovascular disorders. Beta cryptoxanthin compositions and methods herein can reduce body weight body fat glucose levels and free fatty acids when administered in effective amounts. The compositions and methods herein can also reduce oxidative stress on organs such as the eye and liver and/or reduce inflammatory and/or oxidative markers when administered to subjects in need thereof.
